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Abstract
OBJECTIVE: To investigate the effect of Pyunkang-
hwan (Pyunkang-tang) extract (PGT) on secretion
of airway mucin in an experimental animal model
involving hyperplasia of goblet cells and mucus
hypersecretion, and to test its effects on bleomycin
(BLM)-induced pulmonary fibrosis in vivo.
METHODS: The protective activity of orally
administered PGT was assessed in two rat
pulmonary disease models. Effects on
hypersecretion of pulmonary mucin in sulfur
dioxide (SO2)-induced bronchitis in rats were
assessed by quantifying the amount of mucus
secreted and examining histopathology in the
tracheal epithelium. In a rat model for BLM-
induced pulmonary fibrosis, toxicity to the
pulmonary system was examined by measuring
levels of malondialdehyde and hydroxyproline,
indicators of lipid peroxides and collagen,
respectively, in lung tissue 28 days post-BLM
treatment. Serial sections of lung tissue were
stained with Masson trichrome to visualize
collagen deposition. Effects of PGT on collagen
synthesis were also assessed in vitro, in a cell
culture model.
RESULTS: PGT inhibited mucin secretion and
normalized SO2-induced increased muco- sub-
stances in goblet cells. In the BLM- induced model,
PGT decreased the characteristic histopathological
features of lung fibrosis and inhibited fibrotic
lesions, as indicated by decreased hydroxyproline
content. PGT also inhibited the BLM-induced
increase in malondialdehyde levels, demonstrating
its protective effect against lipid peroxidation in
cell membranes of the lung. In MLg 2908 mouse
lung fibroblast cells, PGT decreased transforming
growth factor (TGF)-β-stimulated type I collagen
synthesis.
CONCLUSION: PGT can inhibit both hyper-
secretion of airway mucins and pulmonary fibrosis.
© 2016 JTCM. All rights reserved.
Key words: Pyunkang-hwan (Pyunkang-tang); Air
pollutants; Bleomycin; Pulmonary fibrosis; Airway
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INTRODUCTION
Respiratory mucus is very important for defense
against invading pathogenic microbes, noxious
chemicals and particles. The protective function of
airway mucus is attributed to the viscoelasticity of
mucin. Mucins are multimillion-dalton glycoproteins,
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present in airway mucus, that are produced by goblet
cells in the surface epithelium as well as mucous cells
in the submucosal gland. Hypersecretion of airway
mucus is one of the major symptoms of severe pu-
lmonary diseases, including asthma, chronic bro-
nchitis, cystic fibrosis and bronchiectasis.1 Therefore,
identifying traditional herbal medicines that control
inflammatory hypersecretion of mucins would be
valuable. In addition, fibroblast proliferation and extra-
cellular matrix remodeling are characteristic of
pulmonary fibrosis, the endpoint of a heterogeneous
group of disorders designated as interstitial lung
diseases. Half of all cases of pulmonary fibrosis are
idiopathic pulmonary fibrosis (IPF). IPF is an
intractable disease, with a 5-year survival rate of less
than 50%. The current conventional therapy for IPF is
treatment with corticosteroids, immunosuppressive
drugs and antifibrotic agents.2-5 However, despite int-
ensive investigation, clinical trials of IPF treatments
have been unsuccessful. Therefore, it is important to
investigate whether traditional herbal medicines used
for diverse inflammatory pulmonary diseases can control
pulmonary fibrosis. Bleomycin (BLM), an anti-cancer
agent used to treat some carcinomas, is reported to
provoke pulmonary fibrosis in patients. Therefore,
BLM is used in certain experimental disease models,
producing lung injury and fibrotic lesions in the lung
interstitium in various animal species.6 Intratracheal
instillation of BLM into the lungs of rodents causes an
inflammatory response, alveolar cell damage, fibroblast
proliferation and collagen deposition. In the early
stages of lung damage, BLM produces lesions with
physiological and histopathological similarities to
human fibrotic lung disease.7-15 Interventions designed
to regulate the consequences of the inflammatory
response, such as corticosteroids, anti-tumor necrosis
factor (TNF)-α antibody and anti-transforming growth
factor (TGF)-β antibody, and to protect the lung from
oxidative damage, such as N-acetylcysteine,16 meta-
lloporphyrin17 and Ginkgo biloba extract,18 can inhibit
BLM-induced pulmonary fibrosis. These findings
suggest that inhibition of lung inflammation and lipid
peroxidation may represent therapeutic strategies for
patients with pulmonary fibrosis. In Korea, Pyunkang-
hwan (Pyunkang-tang, PGT), a traditional herbal
preparation consisting of a water extract from six herbs
(Table 1), has been used for controlling hypersecretion
of airway mucus in bronchitis, tonsillitis, pneumonitis
and pulmonary fibrosis.19 Such information indicates
that PGT may have a therapeutic effect on infla-
mmatory hypersecretion of airway mucus and on
pulmonary fibrosis.
Therefore, in this study, we investigated effects of PGT
in two in vivo rat models. Its effects on secretion of
airway mucins were examined in a model involving
hyperplasia of goblet cells and mucus hypersecretion.
In this model, hypersecretion of pulmonary mucins,
resulting from SO2-induced bronchitis, is assessed by
quantifying the amount of mucus secreted and
examining histopathology of the tracheal epithelium.
In addition, we examined effects of PGT on BLM-
induced pulmonary fibrosis. Besides investigating
whether PGT affected the pathologic and biochemical
features of pulmonary fibrosis in the rat model, we also
examined effects of PGT in vitro, on collagen pro-
duction by the MLg 2908 murine lung fibroblast cell
line.
MATERIALS ANDMETHODS
Materials
All chemicals and reagents used in this study were
purchased from Sigma-Aldrich (St. Louis, MO, USA),
unless otherwise specified.
Preparation of PGT
PGT is a preparation consisting of a water extract of
six herbs (Table 1). The six herbs were purchased from
Dae-won-dang Oriental Drug Store (Seoul, Korea) and
identified by Emeritus Professor of Herbology, Chang
Soo Yook (College of Pharmacy, Kyung Hee
University, Seoul, Korea). The following voucher
specimens were deposited at the Herbarium of the
College of Pharmacy, Kyung Hee University, Seoul,
Korea: Lonicerae Flos (Lonicera japonica Thunberg,
Caprifoliaceae), KHUOPS 2013-75; Liriopis Tuber
(Liriope platyphylla Wang et Tang, Liliaceae), KHU-
OPS 2013-76; Adenophorae Radix (Adenophora
tryphilla var. japonica Hara, Campanulaceae), KHU-
OPS 2013-77; Xanthii Fructus (Xanthium strumarium
Linne, Compositae), KHUOPS 2013-78; Selaginellae
Herba (Selaginella tamariscina Spring, Selaginellaceae),
KHUOPS 2013-79; and Rehmanniae Radix Preparata
(Rehmannia glutinosa Liboschitz var. purpurea
Making, Scrophulariaceae), KHUOPS 2013-80. The
six herbs were soaked in 500-mL double-distilled
deionized water and decocted for 150 min at 100 ℃.
The resulting extract was filtered through sterile gauze,
concentrated in a rotary vacuum evaporator and lyo-
philized. PGT (1 g) was prepared from 65 g of a
mixture of the six herbs (yield: 1.5%) and stored at －
70℃ until assayed for its biological actions.
Animals
Pathogen-free male Sprague-Dawley (SD) rats (Daehan
Biolink, Seoul, Korea), 5 weeks old and weighing
200-220 g, were used. The animals were housed five
per cage and were provided distilled water and food ad
libitum. They were kept under a 12 h light/dark cycle
(light 08:00-20:00) at constant temperature (22.5 ℃ )
and humidity (55% ). Animals were cared for in
accordance with the Guide for the Care and Use of
Laboratory Animals regulated by Chungnam National
University, Daejeon, Korea, throughout all of the
experimental procedures.
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Experimental design
To test PGT in the BLM-induced fibrosis model, 30
rats were randomly divided into the following six
groups: control; BLM-only instillation; BLM ins-
tillation with PGT at 157 mg/kg; BLM instillation
with PGT at 314 mg/kg; BLM instillation with PGT
at 785 mg/kg; and BLM instillation with dexa- me-
thasone at 0.5 mg/kg. BLM was administered to the
rats intratracheally (5 mg/kg in 2 mL) and PGT (2 mL
of a dilution providing the indicated dose) was admin-
istered per os. The positive control, dexa- methasone,
was administered by intraperitoneal injection. The
control group was exposed to fresh air in a similar
environment without BLM administration. The day of
intratracheal instillation of BLM was defined as day 0.
Rats were euthanized 28 days after BLM admin-
istration. The lung vasculature was perfused to remove
blood and the left lungs were removed from the
trachea and hilar nodes and weighed. Half of the left
lung was fixed in 4% phosphate-buffered para-
formaldehyde for histo-pathology, while the other half
was frozen in liquid nitrogen for measurement of
collagen and malondialdehyde (MDA). All parameters
were detectable for all groups. To test PGT for effects
on mucus secretion in the rat bronchitis model, another
30 rats were randomly divided into the following six
groups: control; SO2-only exposure; SO2 exposure with
PGT at 157 mg/kg; SO2 exposure with PGT at
314 mg/kg; SO2 exposure with PGT at 785 mg/kg;
and SO2 exposure with dexamethasone at 0.5 mg/kg.
The rats were exposed to SO2 by inhalation and PGT
was administered per os. A positive control, dexa-
methasone, was administered via intraperitoneal
injection. A 10% solution of sodium metabisulfite was
aerosolized into a Plexiglas exposure chamber, using an
ultrasonic humidifier (Samsung Electronics Inc., Seoul,
Korea). The concentration of SO2 gas generated by this
apparatus was measured at 150 ppm. Rats were
exposed to SO2 for 3 h per day, 5 days per week, for
3 weeks, and PGT was administered during the last
2 weeks. The control group was exposed to fresh air in
a similar environment but without SO2 exposure.
Bronchoalveolar lavage fluid (BALF) collection and
quantitation of in vivo mucins in BALF
Rats were euthanized on the last day of the experiment
and the trachea was cannulated using a sterile
polyethylene tube. Bronchoalveolar lavage (BALF) was
performed four times with 5.0 mL ice-cold phosphate-
buffered saline (PBS, pH 7.4) with an 80% recovery
rate. Floating cells and cell debris were removed by
centrifugation of the BALF at 12 000 × g for 5 min.
The BALF supernatants were stored at －70 ℃ until
assayed for mucin content. The amount of mucin in
each BALF sample was measured by enzyme-linked
immunosorbent assay (ELISA). The BALF samples
were diluted at 1∶10 with PBS and 100 mL of each
sample was incubated at 42 ℃ in a 96-well plate until
dry. The plates were washed three times with PBS and
blocked with 2% bovine serum albumin (BSA)
(fraction V) in PBS for 1 h at room temperature. The
plates were again washed three times with PBS and
then incubated with 100 mL per well 45M1 (Neo-
Markers, Fremont, CA, USA), a mouse monoclonal
MUC5AC antibody diluted at 1∶ 200 in PBS
containing 0.05% Tween 20. After 1 h, the wells were
washed three times with PBS, and 100 mL horseradish
peroxidase-goat anti-mouse IgG conjugate (1∶3000 in
PBS) was dispensed into each well. After 1 h, the plates
were washed three times with PBS. The color reaction
was developed with 3, 3′ , 5, 5′-tetramethylbenzidine
(TMB) peroxide solution and stopped with 1 N
H2SO4. The absorbance was read at 450 nm.
Histopathologic analysis of tracheal and lung tissues
Sections were stained with hematoxylin and eosin and
also with Alcian blue for detection of acidic mucins
(stained blue) in tracheal tissues. Formaldehyde-fixed,
paraffin-embedded tracheal tissues were cut into 5 mm
sections. The sections were stained with hematoxylin
and eosin followed by the standard Alcian blue (pH
2.5) method. Alcian blue at pH 2.5 stains all acidic
mucins blue.19 Rat lung tissue samples were fixed in
4% phosphate-buffered paraformaldehyde (pH 7.4)
and processed for routine paraffin embedding. Serial
sections (5 mm) were cut and stained with Masson
trichrome stain and then systematically scanned with a
light microscope to assess the degree of fibrosis. Using
a 40× objective lens, randomly selected fields of each
slide were assessed for gray to greenish blue-stained
collagen.
Preparation and analysis of lung tissue homogenates
Lung tissue samples were homogenized in cold Tris-
HCl-buffered saline (pH 7.4, 10 mmol Tris-HCl,
0.1 mmol EDTA-2Na, 10 mmol saccharose and 0.8%
sodium chloride solution) at 4 ℃ with a Polytron ho-
mogenizer. The tissue homogenates were prepared at
10 % (w/v). Samples were centrifuged at 3000 × g
for 10 min at 4 ℃ and MDA levels and hydroxypro-
line contents in the supernatants were then deter-
mined. MDA level, an indicator of lipid peroxidation,
was determined using a commercial ELISA kit accord-
ing to the manufacturer's instructions (OxiSelect ™
MDA Adduct ELISA Kit, Cell Biolabs, San Diego,
CA, USA). To estimate the collagen content of the
lung, hydroxyproline was measured using a commer-
cial kit according to the manufacturer's instructions
(Hydroxyproline Assay Kit, Sigma-Aldrich).
Murine lung fibroblast culture
MLg 2908, a murine lung fibroblast cell line, was
purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA) and cultured in RPMI
1640 Medium supplemented with 10% fetal bovine
serum in the presence of penicillin (100 units/mL),
streptomycin (100 μg/mL), and HEPES (25 mM) at
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37 ℃ in a humidified water-jacketed incubator
equillibrated with 5% CO2 and 95% air. Cells were
passaged by trypsinization, split 1:4 once weekly, and
used when nearly confluent (70% ). Cells were
trypsinized and seeded onto a 24-well plate at a density
of 5 × 104 cells per well. At confluence, the medium in
the 24-well plates was replaced with serum-free RPMI
1640. After 24-h incubation, the cells were cultured in
the presence of recombinant human transforming
growth factor-β (TGF-β) (10 ng/mL) and serial
concentrations of PGT for 24 h. The supernatants
were then collected for quantification of type Ⅰ
collagen.
Quantification of type I collagen
Type Ⅰ collagen was measured by ELISA. Super-
natants were diluted with PBS at a 1∶10 ratio and
100 mL of each diluted sample was then dispensed
into a 96-well plate. Plates were incubated for 2 h at
room temperature, washed three times with PBS, and
then blocked with 2% BSA (fraction V) in PBS for 1 h
at room temperature. Plates were again washed three
times with PBS and then incubated with 100 mL typeⅠ collagen monoclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), which was diluted
at 1∶500 in PBS containing 0.05% Tween 20. After 1
h, wells were washed three times with PBS and then
100 mL horseradish peroxidase-goat anti-mouse IgG
conjugate (1∶3000 in PBS) was dispensed into each
well. After 1 h, plates were washed three times with
PBS. The color reaction was developed with TMB
peroxide solution and stopped with 1 N H2SO4.
Absorbance was read at 450 nm.
Statistical analysis
The means for each individual group were converted
to percent control and expressed as mean ± standard
error of the mean (SEM). Differences among groups
were assessed using one-way analysis of variance and
the Holm-Šidák test as a post-hoc test using SigmaStat
ver4.0 (Systat Software, San Jose, CA, USA). P < 0.05
was considered significantly different.
RESULTS
Effect of PGT on histopathologic changes in tracheal
tissue and secretion of in vivo airway mucins from
airway goblet cells of rats exposed to SO2
Rats subjected to SO2 exposure for 3 weeks had a
significant increase in mucosubstances (acidic mucins,
stained blue, Figure 1) and mucin secretion in tracheal
tissues (Figure 2) compared with the control group.
However, orally administered PGT inhibited both the
increase of mucosubstances (acidic mucins, stained
blue) in goblet cells of the tracheal tissues and mucin
secretion detected in the BALF. The amounts of mucin
in the BALF samples were 100% ± 19% , 294% ±
27%, 217% ± 11%, 155% ± 13%, 129% ± 9% and
147% ± 23% for the control, SO2-only, SO2 plus PGT
A B C
D E F
Figure 1 Effect of PGT on epithelial mucosubstances in the trachea of rats exposed to sulfur dioxide (hematoxylin and eosin stain-
ing, × 200）
Rats were inhalationally exposed to sulfur dioxide and the effect of orally administered PGT on epithelial mucosubstances (acidic
mucins) in the trachea was investigated, as described in Materials and Methods. The blue staining indicates mucins. A: normal
control group, rats were treated by no specific agent and exposed to fresh and clean air; B: sulfur dioxide group, rats were treated
by no specific agent and exposed to sulfur dioxide; C: section of trachea from rat treated by dexamethasone, a positive control, in-
traperitoneally, and exposed to sulfur dioxide; D: section of trachea from rat treated by PGT 157 mg/kg and exposed to sulfur di-
oxide; E: section of trachea from rat treated by PGT 314 mg/kg and exposed to sulfur dioxide; F: section of trachea from rat treat-
ed by PGT 785 mg/kg and exposed to sulfur dioxide. PGT: Pyunkang-hwan (Pyunkang-tang) extract; SO2: sulfur dioxide.
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157 mg/kg, SO2 plus PGT 314 mg/kg, SO2 plus PGT
785 mg/kg and SO2 plus dexamethasone 0.5 mg/kg
groups, respectively. Dexamethasone, the positive
control, significantly inhibited mucin secretion and the
increase of mucosubstances (acidic mucins) in tracheal
tissues, because of its strong anti-inflammatory activity.
Effect of PGT on histopathologic changes in lung
tissue with BLM-induced pulmonary fibrosis
To elucidate histopathological changes associated with
BLM-induced pulmonary fibrosis and the efficacy of
PGT, left lungs from the different treatment groups
were collected at day 28 post-BLM administration.
Sections were stained with Masson trichrome to
identify collagen. Sections from the control group
displayed normal structures and no pathologic changes
under a light microscope. In the BLM-only group,
marked histopathologic changes, such as large fibrous
areas (deposited collagen, stained gray to greenish blue)
and collapsed alveolar spaces, were evident. In the
BLM-PGT and BLM-dexamethasone groups, the
extent of fibrosis was markedly less severe compared
with in the BLM-only group, as shown in Figure 3.
Effect of PGT on lipid peroxidation in lung tissue
with BLM-induced pulmonary fibrosis
The extent of lipid peroxidation was determined by
measuring lung MDA levels. MDA levels in the lung
of the BLM-only group were significantly increased
compared with the control group. MDA levels in the
BLM-PGT groups and the BLM-dexamethasone
group were lower than in the BLM-only group, as
shown in Figure 4.
Effect of PGT on hydroxyproline content in lung
tissue with BLM-induced pulmonary fibrosis
Deposition of collagen in lung tissue is an established
biomarker of pulmonary fibrosis and hydroxyproline
level is an index of collagen content. The con-
centration of hydroxyproline on day 28 after BLM
instillation was significantly higher in the BLM-only
group than in the normal control group. In the groups
treated with PGT, the hydroxyproline content was
significantly lower than that in the BLM-only group
(Figure 5).
Effect of PGT on murine fibroblast type I collagen
synthesis in vitro
TGF-β significantly increased production of soluble
collagen by MLg 2908 cells. The increase in soluble
collagen levels induced by TGF-β was significantly
inhibited by treatment of the cells with PGT (Figure 6).
DISCUSSION
Hypersecretion of airway mucus is one of the major
symptoms associated with severe respiratory infla-
mmatory diseases. There are two methods of removing
excess mucus from the airways: (a) eliminating the
mucus by physical methods such as aspiration after
dilution of mucus, and (b) pharmacological sup-
pression of mucus secretion. However, in patients, the
physical method irritates the airway luminal wall and
stimulates hypersecretion of mucus through a reflex
mechanism. Therefore, pharmacological regulation of
mucin secretion is important to control airway mucus
hypersecretion. Though glucocorticoids inhibit hyper-
secretion of airway mucins, they have various lim-
itations to their use for this application.1 An alternative
approach for controlling airway mucus hypersecretion
would be to regulate excessive mucin secretion using
traditional herbal medicines that are already used for
management of respiratory inflammatory diseases.
Modulation of inflammatory reactions would be one
of the most appropriate courses of action for treating
diverse pulmonary diseases, including asthma, cystic
fibrosis and chronic obstructive pulmonary diseases. It
is quite difficult to achieve such modulation with
conventional pharmacological agents, while traditional
herbal medicines are potentially an alternative solution,
as indicated by their multiple actions to alleviate the
plural symptoms observed in diverse respiratory infla-
mmatory diseases.
Based on this information, we investigated the effects
of PGT on secretion of airway mucins in an
experimental animal model involving hyperplasia of
Figure 2 Effect of PGT on secretion of in vivo airway mucins
from rats exposed to sulfur dioxide
Rats were inhalationally exposed to sulfur dioxide and the
effect of orally administered PGT on secretion of in vivo
airway mucins was investigated, as described in Materials
and Methods. Normal control group, rats were treated by no
specific agent and exposed to fresh and clean air; Sulfur
dioxide group, rats were treated by no specific agent and
exposed to sulfur dioxide; Section of trachea from rat
treated by dexamethasone, a positive control, intra-
peritoneally, and exposed to sulfur dioxide; Section of
trachea from rat treated by PGT 157 mg/kg and exposed to
sulfur dioxide; Section of trachea from rat treated by PGT
314 mg/kg and exposed to sulfur dioxide; Section of trachea
from rat treated by PGT 785 mg/kg and exposed to sulfur
dioxide. Cont: control; Dexa: dexamethasone; PGT:
Pyunkang-hwan (Pyunkang-tang) extract; S: sulfur dioxide.
Compared with normal control group, aP < 0.05; compared
with sulfur dioxide group, bP < 0.05.
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goblet cells and mucus hypersecretion. Orally admin-
istered PGT inhibited both the increase of acidic
mucins in goblet cells of tracheal tissues and mucin
secretion in BALF (Figures 1 and 2). To our
knowledge, this is the first report on the inhibitory
activity of a complex traditional herbal medicine on
mucin secretion and the amount of mucosubstances
(acidic mucins) in tracheal tissues in animals with
pulmonary inflammation.
A B C
D E F
Figure 3 Effects of PGT on histopathologic changes of the lung induced by bleomycin
Rats were exposed to BLM intratracheally to induce fibrosis and treated as described in Materials and Methods. Twenty-eight days
post-BLM, sampleswere stainedwithMasson trichromeandall panels are shownat the samemagnification, originalmagnification ×
40. A: normal control group, rats were treated by no specific agent and exposed to fresh and clean air; B: bleomycin group, rats
were treated by no specific agent and exposed to bleomycin; C: section of trachea from rat treated by dexamethasone, a positive
control, intraperitoneally, and exposed to bleomycin; D: section of trachea from rat treated by PGT 157 mg/kg and exposed to
bleomycin; E: section of trachea from rat treated by PGT 314 mg/kg and exposed to bleomycin; F: section of trachea from rat
treated by PGT 785 mg/kg and exposed to bleomycin. BLM: bleomycin; PGT: Pyunkang-hwan (Pyunkang-tang) extract.
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Figure 4 Effect of PGT on MDA levels in lung tissue from rats
with BLM-induced pulmonary fibrosis
The experiment was conducted as described for Figure 3,
with lung tissue collected twenty-eight days after BLM.
Except for the control, all groups received BLM. Normal
control group, rats were treated by no specific agent and
exposed to fresh and clean air; Sulfur dioxide group, rats
were treated by no specific agent and exposed to sulfur
dioxide; Section of trachea from rat treated by dexam-n
ethasone, a positive control, intraperitoneally, and exposed
to sulfur dioxide; Section of trachea from rat treated by PGT
157 mg/kg and exposed to sulfur dioxide; Section of trachea
from rat treated by PGT 314 mg/kg and exposed to sulfur
dioxide; Section of trachea from rat treated by PGT 785 mg/
kg and exposed to sulfur dioxide. Cont: control; Bleo/BLM:
bleomycin; Dexa: dexamethasone; MDA: malondialdehyde;
PGT: Pyunkang-hwan (Pyunkang-tang) extract. Compared
with normal control group, aP<0.05; compared with sulfur
dioxide group, bP < 0.05.
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Figure 5 Effect of PGT on hydroxyproline content in rats with
BLM-induced pulmonary fibrosis
Normal control group, rats were treated by no specific agent
and exposed to fresh and clean air; Sulfur dioxide group,
rats were treated by no specific agent and exposed to sulfur
dioxide; Section of trachea from rat treated by dexa-
methasone, a positive control, intraperitoneally, and
exposed to sulfur dioxide; Section of trachea from rat
treated by PGT 157 mg/kg and exposed to sulfur dioxide;
Section of trachea from rat treated by PGT 314 mg/kg and
exposed to sulfur dioxide; Section of trachea from rat
treated by PGT 785 mg/kg and exposed to sulfur dioxide.
Cont: control; Bleo/BLM: bleomycin; Dexa: dexamethasone;
PGT: Pyunkang-hwan (Pyunkang-tang) extract. Compared
with normal control group, aP<0.05; compared with sulfur
dioxide group, bP < 0.05.
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In addition, to investigate the potential therapeutic
effects of PGT on IPF, PGT was administered orally
to rats with BLM-induced pulmonary fibrosis and the
toxicity to the pulmonary system was assessed through
histology and through measurement of MDA and
hydroxyproline in lung tissue 28 days after BLM
treatment. We found that PGT decreased the
characteristic histopathological features of pulmonary
fibrosis. BLM binds to iron (Fe2 + ), undergoes redox
cycling, and catalyzes formation of reactive oxygen
species (ROS).20,21 Free radicals target macromolecules,
such as protein, lipids, and DNA, leading to
progression of lipid peroxidation and resulting in lung
damage. Therefore, overproduction of free-radicals
plays an important role in BLM-induced pulmonary
fibrosis. In this pulmonary fibrosis model, BLM
provoked a significant increase in lipid peroxidation, as
reflected by MDA levels in the BLM-only group, and
treatment with PGT significantly decreased BLM-
stimulated lipid peroxidation. Therefore, it is possible
that the protective effects of PGT on pulmonary
fibrosis may, at least in part, be attributed to its ability
to scavenge ROS generated in the pulmonary system.
Increased collagen in the lung is associated with
increased numbers of interstitial fibroblasts and
increased collagen synthesis by these cells. One strategy
to regulate pulmonary fibrosis would be to inhibit
overproduction of collagen and fibroblast proliferation.
We found that PGT decreased the hydroxyproline
content, an indicator of collagen deposition, in the
lung tissue, compared with that in the BLM-only
group, in vivo. In addition, PGT inhibited the
synthesis of type I collagen stimulated by TGF-β in
vitro. These findings were consistent with our
histopathological observations that PGT inhibited
BLM-induced lung fibrosis.
Taken together, these results might explain, at least in
part, the effectiveness of PGT as an herbal remedy for
treating several pulmonary inflammatory diseases that
are accompanied by hypersecretion of sticky mucus.
Additionally, our results suggested that PGT can be
used as a remedy for various respiratory diseases
provoked by air pollution, since PGT ameliorated
mucus hypersecretion induced by exposure to SO2, a
representative air pollutant produced by the com-
bustion of fossil fuels, including coal. Furthermore,
our results showed that oral administration of PGT
ameliorated BLM-induced pulmonary fibrosis, with
the beneficial effects of PGT included inhibiting lipid
peroxidation induced by BLM in vivo and decreasing
collagen synthesis both in vivo and in vitro. The
underlying mechanism of action of PGT on pul-
monary fibrosis is not clear at present, though we are
investigating whether PGT acts as a potential regulator
of the NF-kB signaling pathway in murine lung
fibroblast cells. It is important to find traditional
herbal medicines and related natural products with
specific inhibitory effects on pulmonary fibrosis, to
advance both basic and clinical science. Though
further studies are required, the results from this study
showed that PGT is a potential therapeutic agent for
pulmonary fibrosis.
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